We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Horizon Therapeutics Public Limited Company | NASDAQ:HZNP | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 116.30 | 116.31 | 116.30 | 0 | 01:00:00 |
From May 2022 to May 2024
By Colin Kellaher
Horizon Therapeutics tumbled in premarket trading Tuesday following a published report that U.S. regulators will move to block the $27.8 billion acquisition of the drugmaker by Amgen.
Bloomberg, citing a person familiar with the matter, late Monday reported that the Federal Trade Commission is expected to file a lawsuit Tuesday to block the deal on the grounds it would hamper innovation and slow the pace of drug development.
Amgen in December said it would pay $116.50 a share in cash for Horizon, marking the largest healthcare merger announced in 2022.
Amgen said it wasn't aware of any FTC decision on the deal, while Horizon deferred comment to Amgen, according to the Bloomberg report.
Horizon shares, which closed Monday at $112.25, were recently down nearly 17% at $93.49 in premarket trading, while Amgen shares edged up 0.6% to $235.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 16, 2023 06:14 ET (10:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Horizon Therapeutics Pub... Chart |
1 Month Horizon Therapeutics Pub... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
